Skip to search formSkip to main contentSkip to account menu

Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01

Known as: FF-10501, FF-10501-01, IMPDH Inhibitor FF-10501 
An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Abstract FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro… 
2019
2019
FF-10501 is a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH). Clinical trials of FF-10501 for myelodysplastic… 
2018
2018
Abstract One of the major symptoms of myelodysplastic syndromes (MDS) is severe cytopenia. Despite cytokine therapies, such as… 
Review
2018
Review
2018
Introduction FF-10501-01 is an orally bioavailable potent inhibitor of inosine-5-monophosphate dehydrogenase (IMPDH). In vitro… 
2016
2016
Resistance to azacitidine is a major issue in the treatments of myelodysplastic syndrome and acute myeloid leukemia, and previous… 
2016
2016
Introduction Inosine 59- monophosphate dehydrogenase (IMPDH) plays a critical role in nucleotide synthesis by serving as a rate… 
2016
2016
Uncontrolled cell proliferation is a hallmark of cancer and requires adequate nucleotide biosynthesis. Inosine monophosphate… 
2015
2015
Inosine 59- monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme that catalyzes de novo synthesis of the guanine… 
Review
2015
Review
2015
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders, characterized by peripheral blood cytopenia and…